Pancreatic Cancer Research

Clinical trialEarly Phase 1Unknown

68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer

Preliminary Study of 68Ga-FAPI-FS PET/CT in Patients With Pancreatic Cancer

Outcome
Outcome unknown
Phase
Early Phase 1
Status
Unknown
Study type
Interventional
Start
1 June 2022
Listed end
1 June 2024
Enrollment
50 participants
Sites
1
Primary outcomes
Adverse events after injection of 68Ga-FAPI-FS
Sponsor type
Academic / other
Results posted
No
Last update
25 May 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a preliminary study of 68Ga-FAPI-FS PET/CT or PET/MR in patients with confirmed or suspicious pancreatic cancer. The goal is to determine the safety, biodistribution, and tumor uptake of 68Ga-FAPI-FS.

Detailed description public domain (ClinicalTrials.gov)

This is a preliminary phase 0 study in patients with confirmed or suspicious pancreatic cancer. Each patient will receive one dose of 68Ga-FAPI-FS by intravenous route. Dedicated whole-body PET/CT imaging will be performed. A comparative 18F-FDG PET/CT will also be performed within a week.